Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8791-8812

  Mariadason, John M ^a   Arango, Diego ^a,d   Shi, Qiuhu ^b   Wilson, Andrew J ^a   Corner, Georgia A ^a   Nicholas, Courtney ^a   Aranes, Maria J ^a   Lesser, Martin ^c   Schwartz, Edward L ^a   Augenlicht, Leonard H ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c N Shore Long Isl Jewish Res Inst ^*  (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; COMPLEMENTARY DNA; FLUOROURACIL; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASE MISPAIRING; BIOSYNTHESIS; COLON CARCINOMA; COLON TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DNA REPAIR; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN CELL; METABOLISM; NUCLEOTIDE SEQUENCE; PREDICTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UNINDEXED SEQUENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE PAIR MISMATCH; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA REPAIR; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9144273781     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322: 352-358, 1990.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
3. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J. Clin. Oncol., 13: 2936-2943, 1995.
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939-944, 1995.
5. Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., and Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 709-715, 1996.
6. Cvitkovic, E., and Bekradda, M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin. Oncol., 26: 647-662, 1999.
7. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
8. Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J. J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J. F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
9. Longley, D. B., Harkin, D. P., and Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 3: 330-338, 2003.
10. Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
11. Metzger, R., Danenberg, K., Leichman, C. G., Salonga, D., Schwartz, E. L., Wadler, S., Lenz, H. J., Groshen, S., Leichman, L., and Danenberg, P. V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res., 4: 2371-2376, 1998.
12. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.
13. Goh, H. S., Yao, J., and Smith, D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55: 5217-5221, 1995.
14. Benhattar, J., Cerottini, J. P., Saraga, E., Metthez, G., and Givel, J. C. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer, 69: 190-192, 1996.
15. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Jr., Stemmerman, G., Wells, J. D., Macdonald, J. S., and Meyskens, F. L., Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res., 58: 1149-1158, 1998.
16. Barratt, P. L., Seymour, M. T., Stenning, S. P., Georgiades, I., Walker, C., Birbeck, K., and Quirke, P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet, 360: 1381-1391, 2002.
17. Elsaleh, H., and Iacopetta, B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin. Colorectal Cancer, 1: 104-109, 2001.
18. Elsaleh, H., Powell, B., McCaul, K., Grieu, F., Grant, R., Joseph, D., and Iacopetta, B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res., 7: 1343-1349, 2001.
19. L in addition to Bax and p53 status. Int. J. Cancer, 98: 498-504, 2002.
20. Augenlicht, L. H., Wadler, S., Corner, G., Richards, C., Ryan, L., Multani, A. S., Pathak, S., Benson, A., Haller, D., and Heerdt, B. G. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res., 57: 1769-1775, 1997.
21. Arango, D., Corner, G. A., Wadler, S., Catalano, P. J., and Augenlicht, L. H. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res., 61: 4910-4915, 2001.
22. cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (Lond.), 419: 729-734, 2002.
23. Arango, D., Mariadason, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., Aranes, M. J., and Augenlicht, L. H. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer, 89: 1757-1765, 2003.
24. Allegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. 89: 1757-1765, 2003. Johnston, P. G., Wolmark, N., and Wieand, H. S. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol., 21: 241-250, 2003.
25. Allegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. 89: 1757-1765, 2003. Johnston, P. G., Wolmark, N., and Wieand, H. S. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol., 21: 241-250, 2003.
26. Johnston, P. G., Benson, A. B., III, Catalano, P., Rao, M. S., O'Dwyer, P. J., and Allegra, C. J. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J. Clin. Oncol., 21: 815-819, 2003.
27. Berglund, A., Edler, D., Molin, D., Nordlinder, H., Graf, W., and Glimelius, B. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res., 22: 3653-3659, 2002.
28. Findlay, M. P., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., and Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer, 75: 903-909, 1997.
29. Johnston, P. G., Drake, J. C., Trepel, J., and Allegra, C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res., 52: 4306-4312, 1992.
30. Mirjolet, J. F., Barberi-Heyob, M., Merlin, J. L., Marchal, S., Etienne, M. C., Milano, G., and Bey, P. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br. J. Cancer, 78: 62-68, 1998.
31. Grem, J. L., Danenberg, K. D., Behan, K., Parr, A., Young, L., Danenberg, P. V., Nguyen, D., Drake, J., Monks, A., and Allegra, C. J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res., 7: 999-1009, 2001.
32. Zembutsu, H., Ohnishi, Y., Tsunoda, T., Furukawa, Y., Katagiri, T., Ueyama, Y., Tamaoki, N., Nomura, T., Kitahara, O., Yanagawa, R., Hirata, K., and Nakamura, Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res., 62: 518-527, 2002.
33. Schwartz, E. L., Baptiste, N., Wadler, S., and Makower, D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem., 270: 19073-19077, 1995.
34. Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br. J. Cancer, 81: 484-489, 1999.
35. Augenlicht, L. H., Wahrman, M. Z., Halsey, H., Anderson, L., Taylor, J., and Lipkin, M. Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res., 47: 6017-6021, 1987.
36. Augenlicht, L. H., Taylor, J., Anderson, L., and Lipkin, M. Patterns of gene expression that characterize the colonic mucosa in patients at genetic risk for colonic cancer. Proc. Natl. Acad. Sci. USA, 88: 3286-3289, 1991.
37. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (Wash. DC), 286: 531-537, 1999.
38. Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D., Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S., and Golub, T. R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (Lond.), 415: 436-442, 2002.
39. Augeron, C., and Laboisse, C. L. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res., 44: 3961-3969, 1984.
40. Whitehead, R. H., Macrae, F. A., St John, D. J., and Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer, J. Natl. Cancer Inst. (Bethesda), 74: 759-765, 1985.
41. Devine, P. L., Birrell, G. W., Whitehead, R. H., Harada, H., Xing, P. X., and McKenzie, I. F. Expression of MUC1 and MUC2 mucins by human tumor cell lines. Tumour Biol., 13: 268-277, 1992.
42. Tibbetts, L. M., Chu, M. Y., Vezeridis, M. P., Miller, P. G., Tibbetts, L. L., Poisson, M. H., Camara, P. D., and Calabresi, P. Cell culture of the mucinous variant of human colorectal carcinoma. Cancer Res., 48: 3751-3759, 1988.
43. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
44. Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. (Bethesda), 88: 173-182, 1996.
45. Loukola, A., Eklin, K., Laiho, P., Salovaara, R., Kristo, P., Jarvinen, H., Mecklin, J. P., Launonen, V., and Aaltonen, L. A. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res., 61: 4545-4549, 2001.
46. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 83: 757-766, 1991.
47. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
48. Mariadason, J. M., Corner, G. A., and Augenlicht, L. H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res., 60: 4561-4572, 2000.
49. Mariadason, J. M., Arango, D., Corner, G. A., Aranes, M., Hotchkiss, K., A., Yang, W., and Augenlicht, L. H. A gene expression profile that defines colon cell maturation in vitro. Cancer Res., 62: 4791-4804, 2002.
50. Cheung, V. G., Morley, M., Aguilar, F., Massimi, A., Kucherlapati, R., and Childs, G. Making and reading microarrays. Nat. Genet., 21: 15-19, 1999.
51. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95: 14863-14868, 1998.
52. Muller, H., Bracken, A. P., Vernell, R., Moroni, M. C., Christians, F., Grassilli, E., Prosperini, E., Vigo, E., Oliner, J. D., and Helin, K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev., 15: 267-285, 2001.
53. Efron, B., and Tibshirani, RJ. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993.
54. Roberts, D. An isotopic assay for thymidylate synthase. Biochemistry, 5: 3546-3548, 1966.
55. Hotchkiss, K. A., Ashton, A. W., Klein, R. S., Lenzi, M. L., Zhu, G. H., and Schwartz, E. L. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res., 63: 527-533, 2003.
56. Wilson, A. J., Arango, D., Mariadason, J. M., Heerdt, B. G., and Augenlicht, L. H. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res., 63: 5401-5407, 2003.
57. Tibbetts, L. M., Chu, M. Y., Hager, J. C., Dexter, D. L., and Calabresi, P. Chemotherapy of cell-line-derived human colon carcinomas in mice immunosuppressed with antithymocyte serum. Cancer (Phila.), 40: 2651-2659, 1977.
58. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet., 24: 227-235, 2000.
59. Dan, S., Tsunoda, T., Kitahara, O., Yanagawa, R., Zembutsu, H., Katagiri, T., Yamazaki, K., Nakamura, Y., and Yamori, T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res., 62: 1139-1147, 2002.
60. Grem, J. L., McAtee, N., Steinberg, S. M., Hamilton, J. M., Murphy, R. F., Drake, J., Chisena, T., Balis, F., Cysyk, R., Arbuck, S. G., et al. A Phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res., 53: 4828-4836, 1993.
61. Remick, S. C., Grem, J. L., Fischer, P. H., Tutsch, K. D., Alberti, D. B., Nieting, L. M., Tombes, M. B., Bruggink, J., Willson, J. K., and Trump, D. L. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res., 50: 2667-2672, 1990.
62. Doniger, S. W., Salomonis, N., Dahlquist, K. D., Vranizan, K., Lawlor, S. C., and Conklin, B. R. MAPPFinder: using Gene Omology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol., 4: R7, 2003.
63. Dahlquist, K. D., Salomonis, N., Vranizan, K., Lawlor, S. C., and Conklin, B. R. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat. Genet., 31: 19-20, 2002.
64. Lazaris, A. C., Kavantzas, N. G., Zorzos, H. S., Tsavaris, N. V., and Davaris, P. S. Markers of drug resistance in relapsing colon cancer. J. Cancer Res. Clin. Oncol., 128: 114-118, 2002.
65. Leppa, S., and Sistonen, L. Heat shock response: pathophysiological implications. Ann. Med., 29: 73-78, 1997.
66. van Belzen, N., Dinjens, W. N., Eussen, B. H., and Bosman, F. I. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol. Histopathol. 13: 1233-1242, 1998.
67. Yung, B. Y., Yang, Y. H., and Bor, A. M. Nucleolar protein B23 translocation after deferoxamine treatment in a human leukemia cell line. Int. J. Cancer, 48: 779-784, 1991.
68. Hirano, J., Wang, X., Kita, K., Higuchi, Y., Nakanishi, H., Uzawa, K., Yokoe, H., Tanzawa, H., Yamaura, A., Yamamori, H., Nakajima, N., Nishikiori, C., and Suzuki, N. Low levels of NPM gene expression in UV-sensitive human cell lines. Cancer Lett., 153: 183-188, 2000.
69. Scorrano, L., and Korsmeyer, S. J. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem. Biophys. Res. Commun., 304, 437-444, 2003.
70. Nita, M. E., Nagawa, H., Tominaga, O., Tsuno, N., Fujii, S., Sasaki, S., Fu, C. G., Takenoue, T., Tsuruo, T., and Muto, T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer, 78: 986-992, 1998.
71. Takechi, T., Koizumi, K., Tsujimoto, H., and Fukushima, M. Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn. J. Cancer Res., 92: 696-703, 2001.
72. Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., and Rozen, R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to flouropyrimidine-based chemotherapy. Clin. Cancer Res., 9: 1611-1615, 2003.
73. Petak, I., Tillman, D. M., and Houghton, J. A. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin. Cancer Res., 6: 4432-4441, 2000.
74. Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S., Howell, S. B., and Boland, C. R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology, 117: 123-131, 1999.
75. Hemminki, A., Mecklin, J. P., Jarvinen, H., Aaltonen, L. A., and Joensuu, H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology, 119: 921-928, 2000.
76. Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M., and Gallinger, S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med., 349: 247-257, 2003.
77. Elsaleh, H., Joseph, D., Grieu, F., Zeps, N., Spry, N., and Iacopetta, B. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet, 355: 1745-1750, 2000.
78. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., and Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
79. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., and Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047, 2000.
80. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
81. Yang, B., Eshleman, J. R., Berger, N. A., and Markowitz, S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res., 2: 1649-1657, 1996.
82. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., and Boothman, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 61: 5193-5201, 2001.
83. Harris, A. L. Hypoxia: a key regulatory factor in tumor growth. Nat. Rev. Cancer, 2: 38-47, 2002.
84. Matthews, N. E., Adams, M. A., Maxwell, L. R., Gofton, T. E., and Graham, C. H. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J. Natl. Cancer Inst. (Bethesda), 93: 1879-1885, 2001.
85. Sakata, K., Kwok, T. T., Murphy, B. J., Laderoute, K. R., Gordon, G. R., and Sutherland, R. M. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer, 64: 809-814, 1991.
86. D'Angio, C. T., and Finkelstein, J. N. Oxygen regulation of gene expression: a study in opposites. Mol. Genet. Metab., 71: 371-380, 2000.
87. Djelloul, S., Forgue-Lafitte, M. E., Hermelin, B., Mareel, M., Bruyneel, E., Baldi, A., Giordano, A., Chastre, E., and Gespach, C. Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett., 406: 234-242, 1997.
88. Wheeler, J. M., Beck, N. E., Kim, H. C., Tomlinson, I. P., Mortensen, N. J., and Bodmer, W. F. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc. Natl. Acad. Sci. USA, 96: 10296-10301, 1999.
89. Jia, L. Q., Osada, M., Ishioka, C., Gamo, M., Ikawa, S., Suzuki, T., Shimodaira, H., Niitani, T., Kudo, T., Akiyama, M., Kimura, N., Matsuo, M., Mizusawa, H., Tanaka, N., Koyama, H., Namba, M., Kanamaru, R., and Kuroki, T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog., 19: 243-253, 1997.
90. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
91. Cottu, P. H., Muzeau, F., Estreicher, A., Flejou, J. F., Iggo, R., Thomas, G., and Hamelin, R. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene, 13: 2727-2730, 1996.
92. Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 87: 7555-7559, 1990.
93. Matsui, S. I., Arredondo, M. A., Wrzosek, C., and Rustum, Y. M. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res., 56: 4715-4723, 1996.
94. Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogelstein, B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res., 55: 5548-5550, 1995.
95. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50: 7717-7722, 1990.
96. Deng, G., Chen, A., Hong, J., Chae, H. S., and Kim, Y. S. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res., 59: 2029-2033, 1999.
97. Gayet, J., Zhou, X. P., Duval, A., Rolland, S., Hoang, J. M., Cottu, P., and Hamelin, R. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene, 20: 5025-5032, 2001.